After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
Hosted on MSN
Where Will Recursion Pharmaceuticals Be in 5 Years?
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Semi-solid-state battery cells engineered by Factorial Energy complete successful validation test with automaker Stellantis. Factorial's FEST (Factorial Electrolyte System Technology) battery cells ...
Stellantis and Factorial Energy have validated a semi-solid state battery cell. The milestone brings the tech one step closer to commercialization. Factorial's cells bring significant advantages in ...
Large Language Models (LLMs) benefit significantly from reinforcement learning techniques, which enable iterative improvements by learning from rewards. However, training these models efficiently ...
Can Java give Python a run for its money in the burgeoning, trendy AI space? While Python still gets top billing when it comes to developing for AI, Java proponents see the nearly 30-year-old Java ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback